Summary Information

Classification Chemicals / Complex Chemical Agents / Type:

(This chemicals section is currently predominantly used in Wildpro to link different data types and demonstrate inter-relationships. It does not contain detailed information on the chemical itself.)

Alternative Names 3TC (B560.14.w14)  (−)-β-L-3'-thia-2',3'-dideoxycytidine (3TC), Epivir®, Zeffix®. (J549.30.w1)
Notes Information in this page has been entered to support the current volumes of Wildpro and further information will be added as new volumes are completed. This page is not intended to substitute for the manufacturer's data sheet and the information is not yet complete for all species, or for all contra-indications etc.

CAUTION: Before any pharmaceutical product is used, the manufacturer's data sheet, containing information on uses, dosage and administration, contra-indications, warnings etc., should always be consulted. It is important to remember that licensing of pharmaceutical products for use in a particular species/condition, as well as mandatory meat and milk withdrawal times for food-producing animals, varies between countries and changes with time. Withdrawal times also may vary between different pharmaceutical formulations and depending on route of administration. In the EU, the prescription cascade must be followed (see LCofC1.2H and W564.Apr05.w1); note that specific restrictions apply for food-producing animals. In the USA, FARAD may be consulted regarding residues and meat and milk withdrawal times.

  • Active against HIV-1, HIV-2 and Herpes B virus. (J549.30.w1)
  • Used in the treatment of HIV infections. (B560.14.w14) in combination with other drugs. (J549.30.w1)
  • An L-stereoisomer nucleoside analogue with an unusual sugar moiety containing a sulphur atom. (B560.14.w14)
  • A competitive inhibitor of/substrate for HIV-RT and an obligate chain-terminator of DNA synthesis. It inhibits HIV-RT more potently than cellular polymerases. (B560.14.w14)
  • Intracellularly phosphorylated to 3TC 5'triphosphate; incorporated by the viral RT as 3TC 5'-monophosphate (diphosphate removed) at the 3' end of the viral DNA chain, acting as a chain terminator. (J549.30.w1)
  • High-level resistance develops quickly in patients (and in cell culture), with a single mutation (codon 184 Met changed to Val or Ile) giving high resistance. The mutation to Valine (M184V) also results in low-level resistance to some nucleoside analogues (e.g. abacavir) but hypersensitivity to others such as AZT and tenofovir). If multiple mutations accumulate, high-level resistance to both AZT and 3TC can result. (B560.14.w14)
  • Given orally, 300 mg once daily or 150 mg twice daily in the treatment of HIv infections. (J549.30.w1)

Return to Top of Page